Study identifier:SD-039-0734
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Efficacy of Symbicort Turbuhaler 160/4.5 mcg as needed versus Oxis 4.5 mcg as needed and Bricanyl 0.4 mg as needed in adults and adolescents with asthma receiving Symbicort Turbuhaler 160/4.5 mcg twice daily as maintenance treatment. A 12-month, randomised, double-blind, parallel-group, active-controlled, phase IIIB, multi-centre study.
asthma
Phase 3
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|